04574nam 2200601Ia 450 991080774160332120230725054529.01-61728-045-3(CKB)2550000000080166(EBL)3018101(SSID)ssj0000742377(PQKBManifestationID)12315868(PQKBTitleCode)TC0000742377(PQKBWorkID)10778945(PQKB)11766619(MiAaPQ)EBC3018101(Au-PeEL)EBL3018101(CaPaEBR)ebr10659023(OCoLC)923655083(EXLCZ)99255000000008016620130317d2010 uy 0engur|n|---|||||txtccrAdvances in medicine and biology[electronic resource] Volume 6 /Leon V. Berhardt, editorNew York Nova Biomedical Booksc20101 online resource (296 p.)Advances in Medicine and Biology ;v.6Description based upon print version of record.1-61668-970-6 Includes bibliographical references and index.""ADVANCES IN MEDICINE AND BIOLOGY VOLUME 6""; ""CONTENTS""; ""PREFACE""; ""ZINC-BASED BIOMATERIALS""; ""BIOLOGICAL ASPECTS OF ZINC""; ""ZINC BIOMATERIALS""; ""ZINC OXYCHLORIDE CEMENTS""; ""ZINC OXIDE EUGENOL CEMENTS""; ""ZINC PHOSPHATE CEMENTS""; ""ZINC POLYCARBOXYLATE CEMENTS""; ""GLASS POLY(ALKENOATE) CEMENTS""; ""GLASSES USED IN GPCS""; ""ACID COMPONENTS USED IN GPCS""; ""THE ROLE OF ADDITIVES TO GPCS""; ""MECHANICAL PROPERTIES OF GPCS""; ""BIOLOGICAL AND ION RELEASE PROPERTIES OF GPCS""; ""ALUMINIUM FREE GPCS""; ""STRUCTURE AND REACTIVITY OF ALUMINIUM FREE IONOMERGLASSES""""STRENGTH OF ALUMINIUM-FREE GPCS""""OPTIMISATION OF RHEOLOGICAL PROPERTIES OF ZN-GPCS""; ""IN VITRO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""IN VIVO ANALYSIS OF ALUMINIUM-FREE GPCS""; ""OTHER ASPECTS OF ALUMINIUM-FREE GPCS""; ""APPLICATIONS FOR ALUMINIUM-FREE GPCS""; ""FUTURE PERSPECTIVES OF ALUMINIUM-FREE GPCS""; ""REFERENCES""; ""THE EFFECTS OF DRUGS ON VERBAL FLUENCY:MECHANISMS OF DRUG RELATED FLUENCY INAPHASIA""; ""ABSTRACT""; ""INTRODUCTION""; ""NEUROANATOMY OF SPEECH AND LANGUAGE""; ""NEUROCHEMICAL BASES OF SPEECH AND LANGUAGE""; ""The Primary Neurotransmitters""""Glutamate, γ-Aminobutyric Acid and Glycine""""Neuromodulators and Hormones""; ""Catecholamines""; ""Acetylcholine""; ""Serotonin""; ""DEFINITION OF FLUENCY""; ""NEUROPHARMACOLOGY OF VERBAL FLUENCY, SPEECH ANDLANGUAGE""; ""Agents which Increase Cerebral Perfusion""; ""Dopaminergic Agents""; ""Amphetamines""; ""Serotonin""; ""Cholinergic Drugs""; ""Piracetam""; ""Zolpidem""; ""Amantadine""; ""Antiepileptic Agents""; ""Drugs which have Speech and Language Side Effects""; ""CLINICAL CASE""; ""CONCLUSION""; ""REFERENCES""; ""PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE""; ""ABSTRACT""""1. CLINICAL FEATURES OF PSORIASIS""""2. TREATMENT OPTIONS FOR PSORIASIS""; ""3. PATHOGENESIS OF PSORIASIS""; ""4. SYSTEMIC MANIFESTATIONS OF INFLAMMATORYDISORDERS""; ""5. CLINICAL LINK BETWEEN PSORIASIS ANDATHEROSCLEROSIS""; ""6. OPHTHALMIC AND RENAL MANIFESTATIONS OFPSORIASIS""; ""7. SIMILARITIES BETWEEN MOLECULAR MECHANISMS OFPSORIASIS AND OTHER INFLAMMATORY DISORDERS""; ""8. CAN TREATMENT OF PSORIASIS ALSO IMPROVE ITSSYSTEMIC MANIFESTATION?""; ""9. DELINEATING PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE: ""5 YEAR VIEW""""; ""REFERENCES""""REPACKAGING OF ANTI-GLAUCOMAMEDICINES:NEW THERAPEUTIC VISTAS""""ABSTRACT""; ""INTRODUCTION""; ""CHOLINERGIC AGENTS""; ""Pilocarpine""; ""NON-SELECTIVE ADRENERGIC AGONISTS""; ""CARBONIC ANHYDRASE INHIBITORS""; ""Acetazolamide""; ""Dorzolamide and Brinzolamide""; ""α2-ADRENERGIC AGONIST""; ""BETA-BLOCKING AGENTS""; ""Timolol""; ""Betaxolol""; ""Levobunolol""; ""Carteolol""; ""PROSTAGLANDIN ANALOGS""; ""Unoprostone Isopropylate""; ""Latanoprost""; ""COMBIMATION""; ""CONCLUSION""; ""REFERENCES""; ""THE UTILIZATION OF TECHNOLOGY IN THETREATMENT OF OBSESSIVE COMPULSIVEDISORDER""; ""ABSTRACT""""INTRODUCTION""Advances in Medicine and BiologyMedicineBiologyMedicine.Biology.616Berhardt Leon V1638158MiAaPQMiAaPQMiAaPQBOOK9910807741603321Advances in medicine and biology3980405UNINA